Vivos Therapeutics Acquires Stake in SOD Sciences for $12 Million

Vivos Therapeutics, Inc. (VVOS) has entered into a definitive agreement to acquire an 11% fully diluted equity stake in SOD Sciences along with 50% co-ownership of its pseudohypoxia test intellectual property. In exchange, Vivos will issue $12 million in new Series C Convertible Preferred Stock. The transaction is expected to close on or about October 15, 2026, subject to customary closing conditions.

The transaction gives Vivos a 50% contribution margin share on test sales, creating a new potential revenue stream. Additionally, issuing the preferred stock could increase company equity, potentially assisting Vivos as it seeks to regain compliance with Nasdaq equity requirements. The preferred shares carry a conversion price of $0.15 per share, representing potential issuance of up to 80 million shares, capped at 19.99% pending shareholder approval.

To realize the long-term benefits of the deal, the transaction must close successfully, receive proper accounting confirmation for equity classification, and secure clinical validation. Investors will also monitor future channel partnerships and commercial adoption as the company targets material revenue starting in 2027. Shares of Vivos Therapeutics were down 5.37% at $0.134 following the announcement.